the India Investment Centre copies of which are available in the Parliament Library.

(d) These details are not available.

(e) According to the available information, apart from M|s. Hoechst (India) Limited, M|s. Albert David and Suneeta Chemicals are producing Tolbutamide and M|s. Searle (India) Limited have produced small quantity of Pheniramine Maleate. Details of stage of manufacture are not known.

Action against M|s. Warner Hindustan

2180. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 184 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether it is a fact that Government have not taken any action against M|s. Warner Hindustan as provided under provision 29 of Drugs Price Control Order for the violation of the provisions of DPCO. 1979; and

(b) if so, what are the reasons therefor?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) Position has already been explained in reply to Rajya Sabha Starred Question No. 19 answered on 18th November, 1985.

Approval of multipurpose plants by M|s Hoechst

2181. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 180 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether the installation of six multipurpose plants by Hoechst was done with Government's approval;

(b) if so, when was the approval of each plan sought by the company;

(c) whether Hoechst is licensed to produce any other bulk drug apart from six being monitored by Government;

(d) if so, names of the bulk drugs along with permitted capacity and stage of manufacture of those bulk drugs allowed;

(e) whether it is a fact that re-endorsement of capacity of Pheniramine Maleate was done with a condition to produce from basic stages;

(f) if so, what are the details of such conditions;

(g) what are the names of other drugs for which re-endorsement of capacity was done along with original and re-endorsed capacity in each case;

(h) whether any condition was imposed while granting re-endorsement of capacity; and

(i) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) Industrial approvals are granted for the manufacture of individual bulk drugs and not in terms of plants. The question of Government approval for multipurpose plant would therefore not arise.

(c) Yes, Sir.

(d) Details of the bulk drugs manufactured to the extent available are furnished in the statement (*See below*)

(e) No capacity has been re-endorsed for Pheniramine Maleate under the existing Policy.

(f) Does not arise.

(g) Details sought are as under:

	Name of the bulk drug	Original capacity	Re-endorsed capacity
(1)	Baralgon Ketone	500 Kgs.	2489 Kgs.
(2)	Frusemide	1200 Kgs.	7148 Kgs.
(3)	Control Serum for tripartigen plates	2000 Nos. x 0.5 mls.	3344 Nos. x 0.5 mls.
(4)	Glybenclamide	200 Kgs.	897 Kgs.

(b) Yes, Sir.

(i) Re-endorsement for Baralgan Ketone, Frusemide and Control Serum for Tripartigen plates contained the condition that 50% of actual production beyond the existing licensed capacity would be made available to the non associated formulators. Re-endorsement for Glybenclamide, in addition to above condition contained the condition that the company shall be required to export 20 per cent of actual production beyond the existing capacity (200 Kgs) in terms of bulk drug or the formulations or combination of both and the company shall not be allowed to import this bulk drug against the REP licences earned through such exports.

Statement

Sl. No.	Name of the bulk drug	Capacity (Tonnes)	Stage of manufacture as reported by the company
1	Fenbendazole	3.500	Basic
2	Benzocaine	2 000	Basic
3	Para-Amino Benzoic Acid	1.200	Basic
4	Isopropyl Antipyrine	30.000	Basic
5	Prenylamine Lactate	8 000	Basic
6	Sodium Salt of N-4 Methylbenzene Sulfonyl Carbamic Acid Methoxyethyl Ester	2.000	Basic
7	Buclosamide	1.070	Basic

Show cause notice to M/s. Glaxo Lab.

2182. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 183 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) when was the show cause notice issued to M|s Glaxo Lab. in regard to unauthorised installation of plant and machinery and when was their explanation received;

(b) what are the reasons for the delay for final decision on the issue;

(c) whether it is a fact that show cause notice was issued on the findings of technical team who made on the spot verification;

(d) if so, what are the details of the findings;

(e) whether it is a fact that unauthorised installation of plant and machinery was made to overproduce those drugs where company is overcharging the prices; and

(f) if so, names of these drugs where company exceeded the permitted capacity along with the licensed capacity and production of drugs during the last three years, year-wise as well as the price fixed for each drug by Government and the price charged by the company?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) A show cause notice was issued to M|s Glaxo Laboratories on the 10th of September, 1984. Their explanation was received in December, 1984.

(b) to (d) No final decision has been taken on the findings of the technical team and the reply of the company, as a policy decision is required to be taken on all such similar cases.